Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 56 min 24 sec ago

CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI(R)

Wed, 09/17/2014 - 12:36
Total Deal Valued at up to Approximately $133.5 Million; Approximately $18.1 million Upfront CTI Retains 100% Commercialization Rights to PIXUVRI in U.S. and Certain E.U. Territories Conference Call Scheduled for Today at 8:30 a.m. EDT SEATTLE, S...
Biopharmaceuticals, Oncology, Licensing
CTI BioPharma, Servier, PIXUVRI, pixantrone, B-cell NHL

Boston Scientific Receives CE Mark For The Vercise(TM) Deep Brain Stimulation (DBS) System For Treating Patients With Tremor

Wed, 09/17/2014 - 12:26
Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life MARLBOROUGH, Mass., Sept. 17, 2014 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (BSX) has received CE Mark for the Ver...
Devices, Neurosurgery, Regulatory
Boston Scientific, Vercise, Deep Brain Stimulation, essential tremor

Dimension Therapeutics Names Annalisa Jenkins as Chief Executive Officer

Tue, 09/16/2014 - 13:11
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases, today announced that Annalisa Jenkins, MBBS, MRCP has been appointed as chief executive offic...
Biopharmaceuticals, Personnel
Dimension Therapeutics, gene therapy

Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners

Tue, 09/16/2014 - 13:08
Funding to Support Development of New Treatments for Drug-Resistant Gram-Negative Bacterial Infections OKLAHOMA CITY, Sept. 16, 2014 -- (Healthcare Sales & Marketing Network) -- Synereca Pharmaceutics, Inc. (SPI), a research-stage biopharmaceutical com...
Biopharmaceuticals, Venture Capital
Synereca Pharmaceutics

First-In-Man Study of the COBRA PzF(TM) Coronary Stent Shows Promising Results Highlighted by Short, 30-Day Dual-Antiplatelet Therapy and Low, 3% TLR Rate

Tue, 09/16/2014 - 13:02
WASHINGTON--(Healthcare Sales & Marketing Network)--CeloNova BioSciences, Inc., today announced that positive First-in-Man (FIM) clinical trial results found its COBRA PzF™ coronary stent system with an advanced nano-thin coating of Polyzene®-F polymer...
Devices, Interventional Cardiology
CeloNova BioSciences, COBRA PzF, coronary stent, Polyzene-F

OncoSec Medical Appoints Dr. Mai H. Le to Position of Chief Medical Officer and Names Dr. Robert H. Pierce as Chief Scientific Officer

Tue, 09/16/2014 - 12:57
Dr. Le to Oversee OncoSec’s Clinical Development and Regulatory Programs; Dr. Pierce to Grow R&D Pipeline SAN DIEGO--(Healthcare Sales & Marketing Network)--OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunothe...
Biopharmaceuticals, Personnel
OncoSec Medical, ImmunoPulse

Venture Backed Catheter Connections Continues to Make False Statements, According to Ivera Medical

Tue, 09/16/2014 - 12:51
SAN DIEGO, CA--(Healthcare Sales & Marketing Network) - In a press release dated September 12, 2014, Catheter Connections continued its pattern of misrepresentation, omission of key facts, and false statements. While the court in Salt Lake City did issue t...
Ivera Medical, Catheter Connections, Curos Tips

NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex(R) for the Treatment of Cystic Fibrosis

Tue, 09/16/2014 - 12:45
Orphan drug designation coincides with dosing of first patients in PhIIa study ABERDEEN, Scotland--(Healthcare Sales & Marketing Network)--NovaBiotics Ltd, the Aberdeen-based clinical-stage biotechnology company (“NovaBiotics” or the “Company”), today a...
Biopharmaceuticals, FDA
NovaBiotics, Lynovex, Cystic Fibrosis, orphan drug designation

Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Tue, 09/16/2014 - 12:39
WHIPPANY, N.J., Sept. 16, 2014 -- (Healthcare Sales & Marketing Network) -- Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral ...
Biopharmaceuticals, Oncology
Bayer HealthCare Pharmaceuticals, Orion Corporation, prostate cancer

Sotera(R) Wireless Names Charlie Alvarez To Lead Sales And Marketing

Mon, 09/15/2014 - 16:04
SAN DIEGO, Sept. 15, 2014 -- (Healthcare Sales & Marketing Network) -- Sotera® Wireless today announced that industry veteran Charlie Alvarez has been appointed senior vice president of sales and marketing. Alvarez will lead the Company's strategic i...
Devices, Monitoring, Personnel
Sotera Wireless

Antares Pharma Announces Promotion of Robert F. Apple to Chief Operating Officer

Mon, 09/15/2014 - 11:20
EWING, N.J.--(Healthcare Sales & Marketing Network)--Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple has been promoted to Chief Operating Officer effective immediately. The Company also announced that a retained search has begun to fill th...
Biopharmaceuticals, Personnel
Antares Pharma, OTREXUP, methotrexate, rheumatoid arthritis

Retina Implant AG's International Clinical Results Presented for the First Time in Europe

Mon, 09/15/2014 - 11:16
Professor Eberhart Zrenner Leads Discussion of Alpha IMS Patient Results One Year Post Implantation at Europe's Largest Ophthalmology Conference LONDON, Sept. 15, 2014 -- (Healthcare Sales & Marketing Network) -- Retina Implant AG, the leading develope...
Devices, Ophthalmology
Retina Implant AG, retinitis pigmentosa, Alpha IMS

Volcano to Showcase Two Novel Commercial Products at TCT 2014: SyncVision(R), and the iFR(R) Modality

Fri, 09/12/2014 - 13:01
Release of these novel precision guidance tools will be demonstrated in live cases, symposia and training programs throughout the week SAN DIEGO, Sept. 12, 2014 -- (Healthcare Sales & Marketing Network) -- Volcano Corporation (VOLC), a leading company ...
Devices, Interventional Cardiology
Volcano, coronary imaging, SyncVision

Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo(TM), and Launches Product With First Commercial Implantations

Fri, 09/12/2014 - 12:54
Symetis Joins Industry Leaders Edwards Lifesciences and Medtronic as Only Companies to Offer Both Transapical and Transfemoral Options for Transcatheter Aortic Heart Valve Delivery LAUSANNE, SWITZERLAND--(Healthcare Sales & Marketing Network) - Symetis ...
Devices, Interventional Cardiology, Product Launch
Symetis, ACURATE neo, transfemoral TAVI, TAVI

Michael C. Kaufmann to Become Chief Financial Officer of Cardinal Health; Jon Giacomin to Lead Pharmaceutical Segment

Thu, 09/11/2014 - 16:55
DUBLIN, Ohio, Sept. 11, 2014 -- (Healthcare Sales & Marketing Network) -- Cardinal Health announced today that Michael C. Kaufmann, 51, has been named chief financial officer of the company effective Nov. 11, 2014. This follows the previously announced pl...
Biopharmaceuticals, Devices, Personnel
Cardinal Health

Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors

Thu, 09/11/2014 - 14:56
BERKELEY HEIGHTS, N.J., Sept. 11, 2014 -- (Healthcare Sales & Marketing Network) -- Cyclacel Pharmaceuticals, Inc. (CYCC) (CYCCP) ("Cyclacel" or the "Company") announced today the appointment of Samuel L. Barker, Ph.D., to its Board of ...
Biopharmaceuticals, Oncology, Personnel
Cyclacel Pharmaceuticals, Sapacitabine

First Surgery in Japan Using InnFocus MicroShunt(TM)

Wed, 09/10/2014 - 13:00
Shirato Eye Clinic of Tokyo is first Japanese center to use the MicroShunt for Glaucoma MIAMI, Sept. 10, 2014 -- (Healthcare Sales & Marketing Network) -- InnFocus, Inc. reported today that the first two surgeries have been conducted in Japan in a clin...
Devices, Ophthalmology
InnFocus, MicroShunt, glaucoma drainage implant

Airway Therapeutics Raises $4.6 Million in Series A Funding

Wed, 09/10/2014 - 12:55
Financing Follows FDA Orphan Designation for Startup Working to Improve Outcomes for Very Premature Infants CINCINNATI, OH--(Healthcare Sales & Marketing Network) - Airway Therapeutics, a biotechnology company working to prevent a debilitating lung cond...
Biopharmaceuticals, Venture Capital
Airway Therapeutics

Avelas Biosciences Extends Series B Financing to $7.4 Million to Support Clinical Development of Real-Time Cancer Visualization Technology

Wed, 09/10/2014 - 12:51
SAN DIEGO, Sept. 10, 2014 -- (Healthcare Sales & Marketing Network) -- Avelas Biosciences, an in vivo cancer diagnostic company dedicated to improving oncologic surgeries, announced today that it has closed on the second tranche of its Series B financing ...
Diagnostics, Oncology, Venture Capital
Avelas Biosciences

Afferent Pharmaceuticals Names Kathleen Sereda Glaub as Chief Executive Officer

Wed, 09/10/2014 - 12:49
SAN MATEO, Calif.--(Healthcare Sales & Marketing Network)--Afferent Pharmaceuticals, a leader in the development of small molecule compounds targeting P2X3 for respiratory, urologic and pain disorders, announced today that Kathleen Sereda Glaub has been na...
Biopharmaceuticals, Personnel
Afferent Pharmaceuticals

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong